Table 1.
Target region | Primer name (sequence 5'-3') | |
LTR | 1R | F: LTR1 (cacacaaggctayttcctga) R: JL17 (cattctgcagcttcctcattgat) |
2R | F: LTR3 (tggatggtgctwcaagytagt) R: LTRrev (tgctagagattttccacactgac) |
|
tat 1st exon | 1R | F: polseq2 (cgggtttattacagggacagc) R: ES33 (cattgccactgtcttctgctc) |
2R | F: TECORI (cagaataggaattctgcgacagagaag) *1 R: TE1 (gggatatgggttgctttgatagagaagc) |
|
tat 2nd exon | 1R | F: KS2mod (ttctatagtggatagagttaggaaggg) R: OFM19mod (gcactcaaggcaagctttattgaggc) |
2R | F: TE2 (gcttctctatcaaagcaacccatatccc) R: TXHOI (acaggctcctcgaggtcgtccc) *2 |
|
β-actin | F: β1 (ggacctgactgactacctcatgaa) R: β2 (gatccacatctgctggaaggtgg) |
1R = 1st round, 2R = 2nd round. Introduced EcoRI (*1) and XhoI (*2) restriction sites are underlined. F: Forward. R: Reverse.